Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.
Arndt H BrachatAlexei A GromNico WulffraatHermine I BrunnerPierre QuartierRiva BrikLiza McCannHuri OzdoganLidia Rutkowska-SakRayfel SchneiderValeria GerloniLiora HarelMaria TerreriKristin HoughtonRik JoosDaniel KingsburyJorge M Lopez-BenitezStephan BekMartin SchumacherMarie-Anne ValentinHermann GramKen AbramsAlberto MartiniDaniel J LovellNanguneri R NirmalaNicolino Rupertonull nullPublished in: Arthritis research & therapy (2017)
Clinicaltrials.gov: NCT00886769 (trial 1). Registered on 22 April 2009; NCT00889863 (trial 2). Registered on 21 April 2009.
Keyphrases
- juvenile idiopathic arthritis
- gene expression
- end stage renal disease
- study protocol
- phase iii
- clinical trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- phase ii
- dna methylation
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- stem cells
- disease activity
- open label
- patient reported outcomes
- systemic lupus erythematosus
- mesenchymal stem cells